Researcher Profile

Researcher Profile

Sheldon Holder, PhD, MD

Sheldon Holder, PhD, MD

Assistant Professor, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Experimental Therapeutics
Disease Teams:
Genitourinary Cancer
slh51@psu.edu

Research Interests

  • Therapeutics
  • Phosphotransferases
  • Neoplasms
  • Renal Cell Carcinoma
  • Prostatic Neoplasms
  • Drug Therapy
  • Kidney Neoplasms
  • Neoplasm Metastasis
  • Recurrence
  • Carcinoma
  • Castration
  • Urinary Bladder Neoplasms

Clinical Trials

MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor).
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome

Recent Publications

2019

Zaleski, M, Gogoj, A, Walter, V, Raman, J, Kaag, MG, Merrill, S, Drabick, J, Joshi, M, Holder, S, Degraff, D & Warrick, J 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system' Human Pathology, vol. 84, pp. 275-282. https://doi.org/10.1016/j.humpath.2018.10.008
Joshi, M, Warrick, J, Yin, M, Holder, S & Drabick, J 2019, 'Need for a personalized approach for muscle invasive bladder cancer: Role of tumor biology in response to neoadjuvant chemotherapy', Translational Andrology and Urology, vol. 8, pp. S99-S103. https://doi.org/10.21037/tau.2018.12.04

2017

Small, J, Washburn, E, Millington, K, Zhu, J & Holder, S 2017, 'The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors', Oncotarget, vol. 8, no. 56, pp. 95116-95134. https://doi.org/10.18632/oncotarget.19618

2016

Matthew, EM, Zhou, L, Yang, Z, Dicker, DT, Holder, S, Lim, B, Harouaka, R, Zheng, S, Drabick, J, Lamparella, NE, Truica, C & El-Deiry, WS 2016, 'A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells', Oncotarget, vol. 7, no. 4, pp. 3662-3676. https://doi.org/10.18632/oncotarget.6657
Al-Marrawi, MY, Mackley, H, Ali, S, Wagner Jr., H, Joshi, M, Holder, S, Kaag, MG, Mallon, C, Talamo, G & Drabick, J 2016, 'Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review', Clinical Genitourinary Cancer, vol. 14, no. 4, pp. e393-e399. https://doi.org/10.1016/j.clgc.2016.01.004
Al-Marrawi, MY & Holder, S 2016, 'Current immunotherapies for renal cell carcinoma', Current Molecular Pharmacology, vol. 9, no. 3, pp. 252-263. https://doi.org/10.2174/1874467208666150716121116
Joshi, M, Millis, SZ, Arguello, D, Holder, S, Lamm, D, Reddy, S, Belani, C, Drabick, J & Vogelzang, NJ 2018, 'Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers', European Urology Focus, vol. 4, no. 1, pp. 94-97. https://doi.org/10.1016/j.euf.2016.06.011
Yin, M, Joshi, M, Meijer, RP, Glantz, M, Holder, S, Harvey, H, Kaag, MG, Van De Putte, EEF, Horenblas, S & Drabick, J 2016, 'Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis', Oncologist, vol. 21, no. 6, pp. 708-715. https://doi.org/10.1634/theoncologist.2015-0440
Joshi, M, Vasekar, M, Grivas, P, Emamekhoo, H, Hsu, JA, Miller, VA, Stephens, PJ, Ali, SM, Ross, JS, Zhu, J, Warrick, J, Drabick, J, Holder, S, Kaag, MG, Li, M & Pal, SK 2016, 'Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma', Oncotarget, vol. 7, no. 32, pp. 52442-52449. https://doi.org/10.18632/oncotarget.9449
Yin, M, Wang, W, Rosenberg, J, Kaag, MG, Joshi, M, Holder, S, Tuanquin, L & Drabick, J 2016, 'Targeted Therapy in Collecting Duct Carcinoma of the Kidney: A Case Report and Literature Review', Clinical Genitourinary Cancer, vol. 14, no. 2, pp. e203-e206. https://doi.org/10.1016/j.clgc.2015.11.008

2015

Holder, S, Drabick, J, Zhu, J & Joshi, M 2015, 'Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer' Cancer Biology and Therapy, vol. 16, no. 2, pp. 207-209. https://doi.org/10.1080/15384047.2014.1002687
Al-Marrawi, MY, Cream, L, Mallon, CA, Holder, S, Joshi, M, Harvey, H, Talamo, G & Drabick, J 2015, 'Effect of topical vaginal androgens in a woman on the testosterone levels of her sexual partner with prostate cancer' Journal of Clinical Oncology, vol. 33, no. 5, pp. 521-522. https://doi.org/10.1200/JCO.2014.59.7773
Wang, W, Cheng, J, Mallon, C, Al-Marrawi, MY, Holder, S, Joshi, M, Kaag, MG, Talamo, G & Drabick, J 2015, 'Symptomatic secondary polycythemia induced by anti-VEGF therapy for the treatment of metastatic renal cell carcinoma: A case series and review' Clinical Genitourinary Cancer, vol. 13, no. 6, pp. e391-e395. https://doi.org/10.1016/j.clgc.2015.07.003
Lipkin, JS, Rizvi, SM, Gatalica, Z, Sarwani, N, Holder, S, Kaag, MG, Drabick, J & Joshi, M 2015, 'Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression' Cancer biology & therapy, vol. 16, no. 1, pp. 28-33. https://doi.org/10.4161/15384047.2014.972843

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)